Skip to content
← All treatment topics

TREATMENT READING

Gestational Trophoblastic Disease

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

32 sections
  1. Treatment Option Overview for Gestational Trophoblastic Disease
  2. Low Levels of hCG
  3. False-positive hCG
  4. Pituitary hCG
  5. Management of Hydatidiform Mole
  6. Treatment of Low-Risk Gestational Trophoblastic Neoplasia (FIGO Score 0–6)
  7. Treatment of High-Risk Gestational Trophoblastic Neoplasia (FIGO Score ≥7)
  8. Treatment of Placental-Site Trophoblastic Tumor
  9. Treatment of Epithelioid Trophoblastic Tumor
  10. Treatment of Recurrent or Chemoresistant Gestational Trophoblastic Neoplasia
  11. Fluorouracil Dosing
  12. Certain factors affect prognosis (chance of recovery) and treatment options.
  13. The treatment of gestational trophoblastic neoplasia is based on the type of disease, stage, or risk group.
  14. Treatment Option Overview
  15. Key Points
  16. There are different types of treatment for patients with gestational trophoblastic disease.
  17. Three types of standard treatment are used:
  18. Surgery
  19. Chemotherapy
  20. Radiation therapy
  21. New types of treatment are being tested in clinical trials.
  22. Treatment for gestational trophoblastic disease may cause side effects.
  23. Patients may want to think about taking part in a clinical trial.
  24. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  25. Follow-up tests may be needed.
  26. Treatment Options for Gestational Trophoblastic Disease
  27. Hydatidiform Moles
  28. Gestational Trophoblastic Neoplasia
  29. Low-risk Gestational Trophoblastic Neoplasia
  30. High-risk Metastatic Gestational Trophoblastic Neoplasia
  31. Placental-Site Gestational Trophoblastic Tumors and Epithelioid Trophoblastic Tumors
  32. Recurrent or Resistant Gestational Trophoblastic Neoplasia

Health professional

Treatment Option Overview for Gestational Trophoblastic Disease

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Most hydatidiform moles (HMs) are benign and are treated conservatively by dilation, suction evacuation, and curettage. However, since they carry a risk of persistence or progression to malignant gestational trophoblastic disease (GTD), they must be followed carefully with weekly serum human chorionic gonadotropin (hCG) levels to normalization. Monthly follow-up for 6 months is generally recommended, although the duration of this phase of follow-up is not based on empiric study.[1]

Sources: 1

Prompt institution of therapy for GTD and continuing follow-up at very close intervals until normal beta-hCG titers are obtained is the cornerstone of management. When chemotherapy is instituted, the interval between courses should rarely exceed 14 to 21 days, depending on the regimen used. It is recommended that patients receive one to three courses of chemotherapy after the first normal beta-hCG titer, depending on the extent of disease. The modified World Health Organization (WHO) Prognostic Scoring System (see Table 1) should be used, and combination chemotherapy should be initiated when warranted by the patient's score. If a diagnosis of GTD is made, routine work-up includes the following:

Sources: Table 1

Serum beta-hCG.

Blood work of liver, renal, and marrow function.

Chest x-ray.

Pelvic ultrasound.

Head computed tomography or magnetic resonance imaging (in the case of choriocarcinoma or central nervous system signs).

Treatment of GTD depends on the risk category determined by the modified WHO Prognostic Scoring System as adapted by the Fédération Internationale de Gynécologie et d’Obstétrique (see Table 1). Since the very rare placental-site trophoblastic tumors and the even more rare epithelioid trophoblastic tumors are biologically distinct entities, their management is discussed separately.

Sources: Table 1

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Gestational Trophoblastic Disease

Low Levels of hCG

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Accurate monitoring of hCG is critical to successfully diagnose and monitor the treatment course of gestational trophoblastic disease. False-positive results may lead to inappropriate diagnoses and treatment, and must be minimized. The following are possible alternate diagnoses to be considered in cases of low-level hCG.

Health professional · Treatment Option Overview for Gestational Trophoblastic Disease / Low Levels of hCG

False-positive hCG

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Serum hCG testing relies on detecting two antibodies on the hCG molecule. The antibodies are polyclonal or monoclonal antibodies derived from various animals: mouse, rabbit, goat or sheep. Humans with heterophilic (or cross-species) antibodies bind the antibodies in the assay, leading to a false-positive result. This was a common problem with one of the commercially available assays until it was re-engineered in 2003. Heterophilic antibodies cannot cross the glomerular filtration barrier, so the performance of a urinary hCG can eliminate this source for a positive test result. The urine sample should be run using the same system generally reserved for serum, as opposed to over-the-counter urine-pregnancy tests, to avoid decreased sensitivity in the latter.

Health professional · Treatment Option Overview for Gestational Trophoblastic Disease / Low Levels of hCG

Pituitary hCG

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

The anterior stalk of the pituitary secretes luteinizing hormone (LH), which shares an alpha subunit with hCG. In normal menstrual cycles, pituitary-generated hCG may be detectable at the time of the LH surge. Estrogen provides negative feedback for this LH secretion and acts as a suppressing agent. In patients in low-estrogen states (perimenopause, menopause, and status postoophorectomy), pituitary hCG may be secreted in increasing amounts, although only levels between 1 to 32 IU/L have been recorded.[2] To confirm a pituitary source for the hCG, patients are started on high-dose oral contraceptive pills to produce an exogenous source of estrogen. In general, patients with pituitary hCG will have their hCG levels suppressed after 3 weeks on this regimen.[2]

Sources: 2 · 2

Health professional

Management of Hydatidiform Mole

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Treatment of hydatidiform mole (HM) is within the purview of the obstetrician/gynecologist and is not discussed separately here. However, following the diagnosis and treatment of HM, patients should be monitored to rule out the possibility of metastatic gestational trophoblastic neoplasia. In almost all cases, this can be performed with routine monitoring of serum beta human chorionic gonadotropin (beta-hCG) to document its return to normal. An effective form of contraception is important during the follow-up period to avoid the confusion that can occur with a rising beta-hCG as a result of pregnancy.

Chemotherapy is necessary when there is the following:

A rising beta-hCG titer for 2 weeks (3 titers).

A tissue diagnosis of choriocarcinoma.

A plateau of the beta-hCG for 3 weeks.

Persistence of detectable beta-hCG 6 months after mole evacuation.

Metastatic disease.

An elevation in beta-hCG after a normal value.

Postevacuation hemorrhage not caused by retained tissues.

Chemotherapy is ultimately required for persistence or neoplastic transformation in about 15% to 20% of patients after evacuation of a complete HM but for fewer than 5% of patients with partial HM. Chemotherapy is determined by the patient's modified World Health Organization score.

In women with complete HM, risk of persistence or neoplastic transformation is approximately doubled in the setting of certain characteristics, which include the following:

Age older than 35 years or younger than 20 years.

Pre-evacuation serum beta-hCG greater than 100,000 IU/L.

Large-for-date uterus.

Large uterine molar mass.

Large (>6 cm) ovarian cysts.

Preeclampsia.

Hyperthyroidism.

Hyperemesis of pregnancy.

Trophoblastic embolization.

Disseminated intravascular coagulation.

Studies have shown that a single course of prophylactic dactinomycin or methotrexate can decrease the risk of a postmolar gestational trophoblastic disease (GTD).[1-3] However, there is concern that chemoprophylaxis increases tumor resistance to standard therapy in the women who subsequently develop GTD.[1] Therefore, this practice is generally limited to countries in which a large number of women do not return for follow-up.

Sources: 1 · 3 · 1

Health professional

Treatment of Low-Risk Gestational Trophoblastic Neoplasia (FIGO Score 0–6)

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

There is no consensus on the best chemotherapy regimen for initial management of low-risk gestational trophoblastic neoplasia (GTN), and first-line regimens vary by geography and institutional preference. Most regimens have not been compared head-to-head, and the level of evidence for efficacy is often limited to C2 except as noted below. Even if there are differences in initial remission rate among the regimens, salvage with alternate regimens is very effective, and the ultimate cure rates are generally 99% or more. The initial regimen is generally given until a normal beta human chorionic gonadotropin (beta-hCG) (for the institution) is achieved and sustained for 3 consecutive weeks (or at least for one treatment cycle beyond normalization of the beta-hCG). A salvage regimen is instituted if any of the following occur:

Sources: C2

A plateau of the beta-hCG for 3 weeks (defined as a beta-hCG decrease of 10% or less for 3 consecutive weeks).

A rise in beta-hCG of greater than 20% for 2 consecutive weeks.

Appearance of metastases.

The use of chemotherapy in the first-line management of low-risk GTN has been assessed in a Cochrane Collaboration systematic review.[1] In that systematic review, four randomized controlled trials were identified.[2-5]

Sources: 1 · 2 · 5

Three of the randomized trials [3-5] compared the same two commonly used regimens:

Sources: 3 · 5

Biweekly (pulsed) dactinomycin (1.25 mg/m2 intravenously [IV]).

Weekly intramuscular (IM) methotrexate (30 mg/m2).

These three trials included a total of 392 patients. In all three trials, patients who received pulsed dactinomycin had better primary complete response rates without the need for additional salvage therapy (relative risk [RR] of cure, 3.00; 95% confidence interval [CI], 1.10–8.17), even though the magnitude of benefit showed substantial heterogeneity (I2 statistic = 79%).[3-5][Level of evidence B1] Fewer courses of dactinomycin therapy were needed to achieve complete response and cure. As expected, salvage chemotherapy was nearly uniformly successful, because almost all low-risk GTN patients are ultimately cured, irrespective of the initial chemotherapeutic regimen. There were no statistically significant differences in most toxicities, including the following:

Sources: 3 · 5 · Level of evidence B1

Nausea and vomiting.

Diarrhea.

Hematologic toxicity.

Hepatic toxicity.

There was a statistically significant increase in dermatologic toxicity, including alopecia, associated with dactinomycin. However, in the largest study,[5] there was more low-grade gastrointestinal toxicity, grade 2 nausea, grade 1 to 2 vomiting, and grades 1 to 3 neutropenia in the dactinomycin group. These values were statistically significant. In this study, patients with choriocarcinoma and risk scores of 5 to 6 had worse complete response rates to initial treatment with single-agent therapy. Methotrexate was virtually ineffective.[5]

Sources: 5 · 5

The fourth randomized trial was very small and included 45 patients. The study compared a 5-day regimen of dactinomycin (10 μg/kg) with an 8-day regimen of methotrexate (1 mg/kg) and leucovorin (0.1 mg/kg) on alternate days. There was a statistically significant decrease in risk of failure to achieve primary cure without the need for salvage therapy in the dactinomycin arm (RR, 0.57; 95% CI, 0.40–0.81).[2][Level of evidence B1] There was less alopecia associated with methotrexate but more hepatic toxicity.

Sources: 2 · Level of evidence B1

The Cochrane systematic review also summarized the evidence from four nonrandomized trials, but comparisons across studies are difficult. The regimens evaluated in those studies are included in the lists below.[1][Level of evidence C2]

Sources: 1 · Level of evidence C2

Commonly used treatment regimens include the following:

The 8-day Charing Cross regimen. Methotrexate (50 mg IM on days 1, 3, 5, and 7) and leucovorin (7.5 mg orally on days 2, 4, 6, and 8). This may be the most common regimen worldwide,[1,6] but it has not been directly compared with other regimens.

Sources: 1 · 6

Biweekly pulsed dactinomycin (1.25 mg/m2 IV).

Weekly methotrexate (30 mg/m2 IM). Efficacy of this regimen appears to be low for choriocarcinoma and for patients with Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) risk scores of 5 to 6.

Other regimens in less-common use include the following:[1]

Sources: 1

An 8-day regimen of methotrexate (1 mg/kg IM on days 1, 3, 5, and 7) and leucovorin (0.1 mg/kg IM on days 2, 4, 6, and 8).

Methotrexate 20 mg/m2 IM on days 1 to 5, repeated every 14 days.

Dactinomycin 12 μg/kg/day IV on days 1 to 5, repeated every 2 to 3 weeks. This regimen is used less often because of substantial alopecia and nausea.

Methotrexate 20 mg IM daily on days 1 to 5; and dactinomycin 500 μg IV daily on days 1 to 5, repeated every 14 days.

Dactinomycin 10 μg/kg/day on days 1 to 5, repeated every 2 weeks.

Methotrexate 0.4 mg/kg/day IM daily on days 1 to 5, repeated after 7 days.

Etoposide 100 mg/m2/day IV on days 1 to 5, or 250 mg/m2 IV on days 1 and 3, at 10-day intervals.[7]

Sources: 7

The unusual patient with a tumor that becomes refractory to single-agent chemotherapy is treated with one of the combination regimens described below for high-risk GTN. For more information, see the Treatment of High-Risk Gestational Trophoblastic Neoplasia (FIGO Score ≥7) section.

Sources: Treatment of High-Risk Gestational Trophoblastic Neoplasia (FIGO Score ≥7)

Health professional

Treatment of High-Risk Gestational Trophoblastic Neoplasia (FIGO Score ≥7)

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Multiagent chemotherapy is standard for the initial management of high-risk gestational trophoblastic neoplasia (GTN). A systematic literature review revealed only one randomized controlled trial (and no high-quality trials)—conducted in the 1980s—comparing multiagent chemotherapy regimens for high-risk GTN.[1] In the trial, only 42 women were randomly assigned to either a CHAMOMA regimen (i.e., methotrexate, leucovorin, hydroxyurea, dactinomycin, vincristine, melphalan, and doxorubicin) or MAC (i.e., methotrexate, dactinomycin, and chlorambucil).[2] There was substantially more life-threatening toxicity in the CHAMOMA arm and no evidence of higher efficacy. However, there were serious methodological problems with this trial. It was reportedly designed as an equivalency trial, but owing to the small sample size, the trial was inadequately powered to assess equivalence. In addition, the characteristics of the patients randomly assigned to the two study arms were not reported (although the authors stated that there were no major differences in the patient populations assigned to each arm), nor was the method of randomization or allocation concealment described.

Sources: 1 · 2

There are no randomized trials comparing regimens in common use to establish the superiority of one over another. Therefore, the literature does not permit firm conclusions about the best chemotherapeutic regimen.[1][Level of evidence C2] However, since EMA/CO (i.e., etoposide, methotrexate, and dactinomycin/cyclophosphamide and vincristine) is the most commonly used regimen, the specifics are provided in Table 2 below.[3-5]

Sources: 1 · Level of evidence C2 · Table 2 · 3 · 5

Table 2. Specifics of the EMA/CO Regimena,b,c
DayDrugDose
IV = intravenously; PO = orally.
aAdapted from Bower et al.[3]
bAdapted from Escobar et al.[4]
cAdapted from Lurain et al.[5]
1Etoposide100 mg/m2 IV for 30 min
Dactinomycin0.5 mg IV push
Methotrexate300 mg/m2 IV for 12 h
2Etoposide100 mg/m2 IV for 30 min
Dactinomycin0.5 mg IV push
Leucovorin15 mg or PO every 12 h × 4 doses, beginning 24 h after the start of methotrexate
8Cyclophosphamide600 mg/m2 IV infusion
Vincristine0.8–1.0 mg/m2 IV push (maximum dose 2 mg)

Sources: 3 · 4 · 5

Cycles are repeated every 2 weeks (on days 15, 16, and 22) until any metastases present at diagnosis disappear and serum beta-human chorionic gonadotropin (beta-hCG) has normalized, then the treatment is usually continued for an additional three to four cycles.

Results of a large, consecutive case series of 272 patients with up to 16 years of follow-up showed a complete remission rate of 78% using this regimen, and these results are consistent with other case series in the literature that employed EMA/CO.[3] More than two-thirds of the women who did not have a complete response or subsequently had disease recurrence could be salvaged with cisplatin-containing regimens (with or without resection of metastases), yielding a long-term cure rate of 86.2% (95% confidence interval, 81.9%–90.5%).[3][Level of evidence C1] Moreover, routinely when the addition of cisplatin plus etoposide was added to EMA/CO, a 9% improvement was reported in the survival results of these high-risk patients.[6] Among the women who had an intact uterus, about 50% retained their fertility. Patients with documented brain metastases received higher doses of systemic methotrexate as part of the EMA component of EMA/CO (1 g/m2 intravenously [IV] for 24 hours, followed by leucovorin rescue, 15 mg orally every 6 hours for 12 doses starting 32 hours after methotrexate). Patients with brain metastases received an increased dose of systemic methotrexate of 1 g/m2 for 24 hours followed by leucovorin (15 mg orally every 6 hours for 12 doses starting 32 hours after methotrexate). Patients with lung metastases received cranial prophylaxis with irradiation and intrathecal methotrexate 12.5 mg every 2 weeks with the CO (i.e., cyclophosphamide and vincristine) cycles.

Sources: 3 · 3 · Level of evidence C1 · 6

Examples of other regimens that have been used include the following:[1]

Sources: 1

MAC: Methotrexate, leucovorin, dactinomycin, and cyclophosphamide.

Another MAC: Methotrexate, dactinomycin, and chlorambucil.

EMA: Etoposide, methotrexate, leucovorin, and dactinomycin (EMA/CO without the CO).

CHAMOCA: Methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine.

CHAMOMA: Methotrexate, leucovorin, hydroxyurea, dactinomycin, vincristine, melphalan, and doxorubicin.

Brain metastases are associated with poor prognosis, particularly when liver metastases are also present.[7-9] However, even patients with brain metastases may achieve long-term remission in 50% to 80% of cases.[3,4,9] Patients with central nervous system (CNS) metastases receive additional therapy simultaneously with the initiation of systemic chemotherapy. Some centers use whole-brain irradiation (30 Gy in 2 Gy fractions) with or without intrathecal methotrexate.[7] However, some investigators omit the cranial radiation, relying on replacement of the standard dose of methotrexate in the EMA/CO regimen with the higher dose of 1,000 mg/m2 IV for 24 hours on the first day, as noted above, to achieve therapeutic CNS levels.[9]

Sources: 7 · 9 · 3 · 4 · 9 · 7 · 9

Health professional

Treatment of Placental-Site Trophoblastic Tumor

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Because placental-site trophoblastic tumors (PSTTs) are rare, reports of therapeutic results are confined to relatively small case series with accrual extending for very long time periods. Therefore, few reliable comparisons among surgical approaches or chemotherapeutic regimens can be made. Nevertheless, there are distinctions in underlying biology between PSTTs and the other gestational trophoblastic tumors—particularly resistance to chemotherapy—that justify specific treatment strategies, such as the following:

Tumors confined to the uterus (Fédération Internationale de Gynécologie et d’Obstétrique [FIGO] Stage I).Hysterectomy is the treatment of choice.[1,2] In a relatively large, retrospective, population-based, consecutive case series of 62 women with PSTT, 33 had disease confined to the uterus and were treated with hysterectomy (n = 17) or with hysterectomy plus chemotherapy (n = 16). Overall survival rates at 10 years were virtually identical between the two groups (90% and 91%, respectively). There was only one recurrence in the surgery group and two in the combination therapy group.[2][Level of evidence C2] There is little evidence to guide the optimal extent of surgery (e.g., lymph node resection or oophorectomy).

Sources: 1 · 2 · 2 · Level of evidence C2

Tumors with extrauterine spread to genital structures (FIGO stage II).Complete resection with or without adjuvant chemotherapy. Because the relapse rate is high after surgery and overall mortality in patients is high, adjuvant multiple-agent chemotherapy should be considered.[1,2][Level of evidence C2] However, the impact of adjuvant therapy on overall mortality is uncertain.

Sources: 1 · 2 · Level of evidence C2

Metastatic tumors (FIGO stages III and IV).Polyagent chemotherapy. A variety of regimens have been used with no direct comparisons to determine whether one is superior. Some of the regimens include the following:[1,2]

Sources: 1 · 2

Metastatic tumors (FIGO stages III and IV).Polyagent chemotherapy. A variety of regimens have been used with no direct comparisons to determine whether one is superior. Some of the regimens include the following:[1,2]

EMA/CO: Etoposide, methotrexate with leucovorin rescue, dactinomycin, cyclophosphamide, and vincristine. This appears to be the most commonly used regimen.

EP/EMA: Etoposide and cisplatin with etoposide, methotrexate, and dactinomycin.

MAE: Methotrexate with leucovorin rescue, dactinomycin, and etoposide.

In part because of the inherent chemoresistance of PSTTs, resection of tumors is often considered in addition to chemotherapy regimens used for high-risk gestational trophoblastic neoplasias. In retrospective series, adjuvant surgery, such as hysterectomy, excision of lung metastases, or removal of obstructing abdominal lesions, has been associated with favorable disease control. However, it is not clear which component of the favorable outcomes is attributable to the surgery or to patient selection factors.[2,3][Level of evidence C2]

Sources: 2 · 3 · Level of evidence C2

Health professional

Treatment of Epithelioid Trophoblastic Tumor

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Epithelioid trophoblastic tumors (ETTs) are exceedingly rare, and there is little information to guide therapy. However, these tumors are similar in behavior and prognosis to placental-site trophoblastic tumors, so it is reasonable to manage them similarly. For more information, see the Treatment of Placental-Site Trophoblastic Tumor section. Few ETTs are malignant in nature, but they are not very responsive to systemic therapy. A variety of chemotherapy regimens have been used.[1]

Sources: Treatment of Placental-Site Trophoblastic Tumor · 1

Health professional

Treatment of Recurrent or Chemoresistant Gestational Trophoblastic Neoplasia

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Recurrent disease indicates failure of prior chemotherapy unless initial therapy was surgery alone. One study found recurrence of disease in 2.5% of patients with nonmetastatic disease, 3.7% of patients with good-prognosis metastatic disease, and 13% of patients with poor-prognosis metastatic disease.[1] Nearly all recurrences occur within 3 years of remission (85% before 18 months). A patient whose disease progresses after primary surgical therapy is generally treated with single-agent chemotherapy unless one of the poor-prognosis factors that requires combination chemotherapy supervenes. Relapse after failure of prior chemotherapy automatically places the patient in the high-risk category. These patients should be treated with aggressive chemotherapy.

Sources: 1

Reports of combination chemotherapy come from small retrospective case series. Long-term disease-free survival, in excess of 50%, is achievable with combination drug regimens.[2][Level of evidence C2] A variety of regimens have been reported that include combinations of the following:[3-7]

Sources: 2 · Level of evidence C2 · 3 · 7

Cisplatin.

Etoposide.

Bleomycin.

Ifosfamide.

Paclitaxel.

Fluorouracil.

Floxuridine.

A select group of patients with chemotherapy-resistant and clinically detectable gestational trophoblastic neoplasia may benefit from salvage surgery.[8][Level of evidence C2]

Sources: 8 · Level of evidence C2

Health professional · Treatment of Recurrent or Chemoresistant Gestational Trophoblastic Neoplasia

Fluorouracil Dosing

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[9,10] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[9-11] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[12-14] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[15] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[16]

Sources: 9 · 10 · 9 · 11 · 12 · 14 · 15 · 16

For patients · General Information About Gestational Trophoblastic Disease

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Gestational trophoblastic disease usually can be cured. Treatment and prognosis depend on the following:

Sources: cured · prognosis

The type of GTD.

Whether the tumor has spread to the uterus, lymph nodes, or distant parts of the body.

The number of tumors and where they are in the body.

The size of the largest tumor.

The level of beta-hCG in the blood.

How soon the tumor was diagnosed after the pregnancy began.

Sources: diagnosed

Whether GTD occurred after a molar pregnancy, miscarriage, or normal pregnancy.

Previous treatment for gestational trophoblastic neoplasia.

Treatment options also depend on whether the woman wishes to become pregnant in the future.

For patients · Stages of Gestational Trophoblastic Tumors and Neoplasia

The treatment of gestational trophoblastic neoplasia is based on the type of disease, stage, or risk group.

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Invasive moles and choriocarcinomas are treated based on risk groups. The stage of the invasive mole or choriocarcinoma is one factor used to determine risk group. Other factors include the following:

Sources: Invasive moles · choriocarcinomas · risk groups

The age of the patient when the diagnosis is made.

Sources: diagnosis

Whether the GTN occurred after a molar pregnancy, miscarriage, or normal pregnancy.

Sources: molar pregnancy · pregnancy

How soon the tumor was diagnosed after the pregnancy began.

The level of beta human chorionic gonadotropin (beta-hCG) in the blood.

Sources: beta human chorionic gonadotropin

The size of the largest tumor.

Where the tumor has spread to and the number of tumors in the body.

How many chemotherapy drugs the tumor has been treated with (for recurrent or resistant tumors).

Sources: chemotherapy · drugs · recurrent

There are two risk groups for invasive moles and choriocarcinomas: low risk and high risk. Patients with low-risk disease usually receive less aggressive treatment than patients with high-risk disease.

Sources: aggressive

Placental-site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT) treatments depend on the stage of disease.

For patients

Treatment Option Overview

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

There are different types of treatment for patients with gestational trophoblastic disease.

Three types of standard treatment are used:

Three types of standard treatment are used:

Surgery

Chemotherapy

Radiation therapy

New types of treatment are being tested in clinical trials.

Treatment for gestational trophoblastic disease may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with gestational trophoblastic disease.

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Different types of treatment are available for patients with gestational trophoblastic disease. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. Before starting treatment, patients may want to think about taking part in a clinical trial. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.

Sources: gestational trophoblastic disease · clinical trials · research study · cancer · standard treatment

Clinical trials are taking place in many parts of the country. Information about ongoing clinical trials is available from the NCI website. Choosing the most appropriate cancer treatment is a decision that ideally involves the patient, family, and health care team.

Sources: NCI website

For patients · Treatment Option Overview

Three types of standard treatment are used:

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

For patients · Treatment Option Overview / Three types of standard treatment are used:

Surgery

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

The doctor may remove the cancer using one of the following operations:

Dilatation and curettage (D&C) with suction evacuation: A surgical procedure to remove abnormal tissue and parts of the inner lining of the uterus. The cervix is dilated and the material inside the uterus is removed with a small vacuum-like device. The walls of the uterus are then gently scraped with a curette (spoon-shaped instrument) to remove any material that may remain in the uterus. This procedure may be used for molar pregnancies.

Sources: Dilatation and curettage · suction evacuation · surgical · abnormal · tissue · uterus · cervix · dilated · device · curette

Hysterectomy: Surgery to remove the uterus, and sometimes the cervix. If the uterus and cervix are taken out through the vagina, the operation is called a vaginal hysterectomy. If the uterus and cervix are taken out through a large incision (cut) in the abdomen, the operation is called a total abdominal hysterectomy. If the uterus and cervix are taken out through a small incision (cut) in the abdomen using a laparoscope, the operation is called a total laparoscopic hysterectomy.

Sources: Hysterectomy · Surgery · vagina · incision · abdomen · laparoscope

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · cells · adjuvant therapy

For patients · Treatment Option Overview / Three types of standard treatment are used:

Chemotherapy

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated, or whether the tumor is low-risk or high-risk.

Sources: drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · organ · cavity · regional chemotherapy · stage · tumor

Combination chemotherapy is treatment using more than one anticancer drug.

Sources: Combination chemotherapy

See Drugs Approved for Gestational Trophoblastic Disease for more information.

Sources: Drugs Approved for Gestational Trophoblastic Disease

For patients · Treatment Option Overview / Three types of standard treatment are used:

Radiation therapy

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:

Sources: Radiation therapy · x-rays · radiation

External radiation therapy uses a machine outside the body to send radiation toward the cancer.

Sources: External radiation therapy

Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.

Sources: Internal radiation therapy · radioactive · seeds · catheters

The way the radiation therapy is given depends on the type of gestational trophoblastic disease being treated. External radiation therapy is used to treat gestational trophoblastic disease.

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for gestational trophoblastic disease may cause side effects.

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

Blood levels of beta human chorionic gonadotropin (beta-hCG) will be checked for up to 6 months after treatment has ended. This is because a beta-hCG level that is higher than normal may mean that the tumor has not responded to treatment or it has become cancer.

Sources: Blood · beta human chorionic gonadotropin · responded

For patients

Treatment Options for Gestational Trophoblastic Disease

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

For patients · Treatment Options for Gestational Trophoblastic Disease

Hydatidiform Moles

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Treatment of a hydatidiform mole may include the following:

Sources: hydatidiform mole

Surgery (Dilatation and curettage with suction evacuation) to remove the tumor.

Sources: Surgery · Dilatation and curettage · suction evacuation · tumor

After surgery, beta human chorionic gonadotropin (beta-hCG) blood tests are done every week until the beta-hCG level returns to normal. Patients also have follow-up doctor visits monthly for up to 6 months. If the level of beta-hCG does not return to normal or increases, it may mean the hydatidiform mole was not completely removed and it has become cancer. Pregnancy causes beta-hCG levels to increase, so your doctor will ask you not to become pregnant until follow-up is finished.

Sources: beta human chorionic gonadotropin · blood · follow-up · cancer · Pregnancy

For disease that remains after surgery, treatment is usually chemotherapy.

Sources: chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment Options for Gestational Trophoblastic Disease

Gestational Trophoblastic Neoplasia

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

For patients · Treatment Options for Gestational Trophoblastic Disease / Gestational Trophoblastic Neoplasia

Low-risk Gestational Trophoblastic Neoplasia

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Treatment of low-risk gestational trophoblastic neoplasia (GTN) (invasive mole or choriocarcinoma) may include the following:

Sources: neoplasia · invasive mole · choriocarcinoma

Chemotherapy with one or more anticancer drugs. Treatment is given until the beta human chorionic gonadotropin (beta-hCG) level is normal for at least 3 weeks after treatment ends.

Sources: Chemotherapy · drugs · beta human chorionic gonadotropin

If the level of beta-hCG in the blood does not return to normal or the tumor spreads to distant parts of the body, chemotherapy regimens used for high-risk metastatic GTN are given.

Sources: blood · tumor · regimens · metastatic

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment Options for Gestational Trophoblastic Disease / Gestational Trophoblastic Neoplasia

High-risk Metastatic Gestational Trophoblastic Neoplasia

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Treatment of high-risk metastatic gestational trophoblastic neoplasia (invasive mole or choriocarcinoma) may include the following:

Sources: metastatic · neoplasia · invasive mole · choriocarcinoma

Combination chemotherapy.

Sources: Combination chemotherapy

Intrathecal chemotherapy and radiation therapy to the brain (for cancer that has spread to the lung, to keep it from spreading to the brain).

Sources: Intrathecal chemotherapy · radiation therapy · cancer · lung

High-dose chemotherapy or intrathecal chemotherapy and/or radiation therapy to the brain (for cancer that has spread to the brain).

Sources: High-dose chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment Options for Gestational Trophoblastic Disease / Gestational Trophoblastic Neoplasia

Placental-Site Gestational Trophoblastic Tumors and Epithelioid Trophoblastic Tumors

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Treatment of stage I placental-site gestational trophoblastic tumors and epithelioid trophoblastic tumors may include the following:

Sources: stage · tumors

Surgery to remove the uterus.

Sources: Surgery · uterus

Treatment of stage II placental-site gestational trophoblastic tumors and epithelioid trophoblastic tumors may include the following:

Surgery to remove the tumor, which may be followed by combination chemotherapy.

Sources: combination chemotherapy

Treatment of stage III and IV placental-site gestational trophoblastic tumors and epithelioid trophoblastic tumors may include following:

Combination chemotherapy.

Surgery to remove cancer that has spread to other places, such as the lung or abdomen.

Sources: cancer · lung · abdomen

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment Options for Gestational Trophoblastic Disease

Recurrent or Resistant Gestational Trophoblastic Neoplasia

Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 25, 2022. Captured 2026-09-09.

Treatment of recurrent or resistant gestational trophoblastic tumor may include the following:

Sources: recurrent · gestational trophoblastic tumor

Chemotherapy with one or more anticancer drugs for tumors previously treated with surgery.

Sources: Chemotherapy · tumors · surgery

Combination chemotherapy for tumors previously treated with chemotherapy.

Sources: Combination chemotherapy

Surgery for tumors that do not respond to chemotherapy.

Sources: respond

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Disease and treatment settings

Gestational Trophoblastic Disease

Disease and treatment setting

Gestational Trophoblastic Disease

metastatic Gestational Trophoblastic Disease

Disease and treatment setting

High-risk Metastatic Gestational Trophoblastic Neoplasia

recurrent Gestational Trophoblastic Disease

Disease and treatment setting

Treatment of Recurrent or Chemoresistant Gestational Trophoblastic Neoplasia